ClinicalTrials.gg
Status unknownNCT05849558URSO-003Updated May 9, 2023

Study to Compare the Efficacy & Safety of Ursoplus Capsules vs. UDCA vs. Placebo Among Chronic Liver Disease Patients

A Phase 4 interventional study of Ursoplus and UDCA 250mg in Chronic Liver Disease, sponsored by MinaPharm Pharmaceuticals. Status unknown at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-09.

Sponsored by MinaPharm Pharmaceuticals · Phase 4, Interventional, and Treatment

How we know

The sponsor has not verified this record recently (last verified Apr 2023), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Feb 2022, registered Apr 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
297
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study aims to compare the efficacy \& safety of Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg) versus UDCA alone versus Placebo among Compensated Chronic Liver Diseased Patients

Read the detailed description

Research Question:

Compare the efficacy \& safety of Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg) versus UDCA alone versus Placebo among Compensated chronic liver diseased patients

Primary Objective:

To assess the efficacy of Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg) versus UDCA 250mg alone and versus Placebo in the reduction of total serum bilirubin, Direct serum bilirubin and elevated liver Enzymes from baseline to End of Treatment (EOT)

Secondary Objectives:

  • To assess the efficacy of Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg) versus UDCA 250 mg alone and versus Placebo in reducing the degree of steatosis as measured by Vibration-controlled transient elastography with Controlled Attenuation Parameter (CAP)
  • To assess the safety of Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg) versus UDCA 250 mg alone and versus Placebo among compensated Chronic Liver Diseased Patients
  • To describe improvement in quality of life for patients after treatment

A study population of 297 patients suffering from compensated chronic Liver Disease, who will be randomized according to Vibration-controlled transient elastography in screening visit into 2 groups:

  • Group 1: with non-cirrhosis, F0, F1 and F2.
  • Group 2: with advanced fibrosis and cirrhosis, F3 and F4.

Each group will receive either Ursoplus® capsules (UDCA 250mg \& Silymarin 140mg), or UDCA alone or Placebo, through Stratified random sampling.

Duration for enrollment: 6 months Total duration of the study/subject will be approximately: 6 months for treatment and follow-up visits including the screening visit

Subjects will be enrolled for a duration of 6 months including the screening visit

  • Screening visit 1 (Treatment initiation)
  • Visit 2: after 1st month, follow-up 1
  • Visit 3: after 2nd month, follow-up 2
  • Visit 4: after 3rd month, follow-up 3
  • Visit 5: after 4th month, follow-up 4
  • Visit 6: after 5th month, follow-up 5
  • End of Study visit, after 6th month of treatment, follow-up 6
02

Conditions studied

  • Chronic Liver Disease
03

In context

Lead sponsor

MinaPharm Pharmaceuticals is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male and female patients aged ≥ 18
  2. Subjects with Compensated Chronic Liver Disease, defined as child 5-7.
  3. Patients with mild disturbance of liver biochemical profile (elevated Total Serum ≤ 3 mg/dl, or elevated Direct Serum Bilirubin ≤ 2 mg/dl, or elevated one or more of liver enzymes, up to 3 times of the normal level ( (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) \& Gamma Glutamyl Transpeptidase (GGT)).
  4. Non-diabetic subjects and subjects with Controlled DM-type 1 and 2 patients, up to 7.5%
  5. Non-pregnant or lactating female patients
  6. Subjects who are willing to sign Form (ICF) and ready to comply with the protocol for the duration of the study

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a history of to any of the ingredients of the medications being studied
  2. Subjects with positive PCR/or antibodies to in the past 6 months
  3. Subjects with positive surface antigen (HBsAg)
  4. Subjects with elevated liver enzymes more than 3 times of the normal level (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP) \& Gamma Glutamyl Transpeptidase (GGT).
  5. Subjects with Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC).
  6. Subjects with Score more than 7.
  7. Subjects with history of bleeding varices.
  8. Subjects having uncontrolled Diabetes (HbA1cmore than 7.5 %)
  9. Subjects with any medical condition requiring the usage of medication that may interfere with the absorption, distribution, metabolism or excretion of the study drug such as:

    1. Bile acid sequestering agents such as cholestyramine and colestipol.
    2. Antacids containing aluminum hydroxide.
    3. Drugs affecting lipid metabolism such as estrogens, oral and hormonal , and clofibrate (and perhaps other lipid-lowering drugs)
  10. Subjects who are receiving other liver support drugs (including drugs of the study), 1 month before study initiation.
  11. Subjects with auto immune liver disease taking or immune suppressant
  12. Pregnant or breast-feeding women
  13. Use of oral contraceptives in child bearing ladies
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
297 participants (estimated)

Study arms

  • Experimental
    Ursoplus® capsules (UDCA 250mg & Silymarin 140mg)

    Ursoplus® capsules: UDCA 250mg \& Silymarin 140mg 2 Capsules every 12 hours

    Drug: Ursoplus

  • Active comparator
    UDCA 250mg

    UDCA capsules: UDCA 250mg 2 Capsules every 12 hours

    Drug: UDCA 250mg

  • Placebo comparator
    Placebo

    Placebo alone 2 Capsules every 12 hours

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Total serum bilirubin

    Change in mean Total serum bilirubin from baseline (visit 1) to End of study between the 3 treatment groups

    Time frame: Up to 6 months

  2. Change in Direct Serum Bilirubin

    Change in mean Direct Serum Bilirubin from baseline (visit 1) to End of study between the 3 treatment groups

    Time frame: Up to 6 months

  3. Change in Elevated Liver Enzymes

    Change in mean AST \& ALT from baseline (visit 1) to End of study between the 3 treatment groups

    Time frame: Up to 6 months

Secondary outcomes

  1. Improved degree of Steatosis

    Change in the mean score of Controlled Attenuation Parameter (CAP) from baseline (visit 1) to End of study between the 3 treatment groups, measured by Vibration-controlled transient elastography

    Time frame: Up to 6 months

  2. Improved quality of life

    Change in the mean Score of different items of the RAND 36-Item Health Survey between the 3 treatment groups after 3 months (visit 4) and 6 months of treatment (End of study visit).

    Time frame: Up to 6 months

  3. Incidence of adverse events (AEs)

    Percent of serious (SAEs)/ non-serious adverse events (AEs), including percent changes in lab tests and percent of AEs leading to permanent discontinuation of the study drug.

    Time frame: Up to 6 months

07

Study locations

1 of 1 sites recruiting
  • Air Force Specialized Hospital
    Cairo, New Cairo, Egypt
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2022 (actual). Primary completion is estimated for Dec 2023, 22 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2023
First posted
May 9, 2023
StartActual
Feb 22, 2022
Primary completionEst.
Dec 31, 2023
CompletionEst.
Dec 31, 2023
Last update
May 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05849558
Lead sponsor
MinaPharm Pharmaceuticals
Responsible party
Sponsor
First posted
May 9, 2023
Start date
Feb 22, 2022
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
May 9, 2023

Study contacts

Gamal Dr Esmat, PhD
Contact
g_esmat@yahoo.com
+202 01222455468
Mohamed Dr El Kassas, PhD
Contact
m_elkassas@yahoo.com
+2 01114455552-
Gamal Dr Esmat, PhD
principal investigator · Air Force Specialized Hospital
Mohamed El Kassas, PhD
principal investigator · Helwan University Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion